The 5% Shuffle – How not to get funded
Before you go ahead and pitch your potential to capture some percentage of a market, read this article. Bottom line: market’s aren’t captured, spending budgets are. Focus on capturing your customer’s budgets, not the “market.”
A Drug Behemoth In The Making?
“Novartis plus Aventis would create the world’s No. 2 drugmaker, unless politics get in the way “
Is genetic engineering next doping threat?
Experts worry that biotechnology could infiltrate sports
Boy May Force Change in Norway Bio-Ethics Law
“A campaign to save a six-year-old Norwegian boy with a life-threatening blood disorder looked likely Thursday to force Norway to relax strict biotechnology laws in a stinging defeat for the government. “
Drug Prices: The Genentech Solution
“If developed nations want access to breakthrough medicines, they should have to pay full price, says Genentech Chief Executive Arthur D. Levinson. “
Amgen Opens The Secret Curtain
“The biotech leader will host analysts and investors to drum up excitement for its pipeline — and its stock. Will it work? “
Biotech uptick moves into March:
“February went out like a lion in biotechnology as filings for initial public offerings (IPOs) by three companies capped a flurry of activity in the sector. Acadia Pharmaceuticals, Alnylam Pharmaceuticals, and Ark Therapeutics announced filings in the wake of strong openings on Wall Street last month for GTx, Renovis, Corgentech, and DynaVax Technologies.”
And When ImClone’s Drug Doesn’t Work…
It’s not all roses for Erbitux: “The drug dramatically shrinks colon tumors in some patients. But in others, it has little effect — and no one knows why. “